The cerebrospinal fluid management market size is expected to reach US$ 2,892.54 million by 2030 from US$ 1,911.37 million in 2022; it is estimated to record a CAGR of 5.3% from 2022 to 2030.
The growing demand for better treatment modalities has resulted in various product developments in the last few decades. A few of the examples of recent product developments in the CSF management market are mentioned below.
•In September 2022, Anuncia Medical Inc received US Food and Drug Administration (FDA) approval for its ReFlow System Mini for the treatment of patients with hydrocephalus and other cerebrospinal fluid disorders that require shunting. ReFlow System Mini noninvasively facilitates a flush of ventricular catheters to restore, increase, or maintain CSF flow in a shunt.
•In March 2021, the FDA granted a breakthrough device designation for the ReFlow System of Anuncia for CSF management. The device is designed to treat CSF disorders such as hydrocephalus, which require shunting. ReFlow system can be used in homecare settings and in clinics for prophylactic flushing that is performed noninvasively to potentially prevent CSF blockages.
•In June 2020, the FDA granted Breakthrough Device Designation to the FlowSense wireless, noninvasive flow sensor offered by Rhaeos, Inc. The product is designed to rapidly monitor ventricular shunt function in patients with excess cerebrospinal fluid caused by hydrocephalus.
Increasing Focus on CSF Management in Neurological Disease Treatments Provides New Opportunities for the Cerebrospinal Fluid Management Market
CSF parameters are extensively evaluated as biomarkers of neurological disorders in adult patients. Circulating microRNAs in CSF are a promising class of biomarkers for the diagnosis of various neurological diseases. Neurological disorders such as Parkinson’s Disease (PD), Alzheimer’s Disease (AD), epilepsy, and seizures often lead to altered CSF parameters. According to an article published in Nature, 76 CSF proteins were found to be structurally altered in patients that were diagnosed with PD when compared to normal individuals. The study also suggests that these CSF proteins can be used as biomarkers for the diagnosis or treatment of the disease. PD is a neurodegenerative disease associated with loss of cognitive impairment and motor function. According to the World Health Organization (WHO) report published in 2022, the prevalence of PD has doubled in the last 25 years, affecting ~1% of the global population aged more than 60 years. Similarly, a few of the CSF parameters such as protein and lactate levels are altered in patients suffering from seizure or status epilepticus. Therefore, various R&D activities are going on for using CSF parameters in the treatment of seizures or epilepsy. Further, despite the availability of various CSF assays for the detection of Alzheimer’s disease using CSF in the market, there are unmet needs for biomarkers for detection and treatment purposes. As the detection of cases of Alzheimer’s disease and PD increases, there is increase in demand for CSF management devices as the cases of CSF leaks may increases. Therefore, a rise in the prevalence of neurological disorders is fueling the research and development activities for the use of CSF management products in the treatment of these disorders.
The cerebrospinal fluid management market is segments into product and end user. Based on product, the market is bifurcated into CSF shunts and CSF drainage systems. In 2022, the CSF shunts segment held the largest share of the market by product. and the same segment is estimated to grow at a significant CAGR during the forecast period due to growing product launches, increasing demand for advanced CSF shunts, and increasing incidences of hydrocephalus. CSF shunts was further segmented into ventriculoperitoneal shunts, ventriculoatrial shunts, ventriculopleural shunts, and lumboperitoneal shunts. Based on CSF shunts, ventriculoperitoneal shunts held the largest market share of cerebrospinal fluid management market and is expected to grow at a fastest CAGR during the forecast period. Similarly, the CSF drainage systems were classified into external ventricular drainage (EVD) systems and lumbar drainage (LD) systems. External ventricular drainage systems are the more commonly used CSF drainage systems in the industry therefore, marking largest share of the segment.
Based on geography, the market is segmented into North America, Europe, Asia Pacific Middle East & Africa, and South & Central America. North America held the largest market share of the cerebrospinal fluid management market. The market in North America is expected to continue its dominance during the forecast period due to the increasing hydrocephalus, traumatic brain injury, and other neurological condition incidences; rapid technological innovations; and developing healthcare infrastructure. Whereas Asia Pacific is the fastest growing region in the market owing to the factors, including growing geriatric population, demand for advanced medical devices, and increasing healthcare infrastructures offering efficient treatments.
The growth of cerebrospinal fluid management market is defined by some of the key factors, such as increasing incidences of CSF leak and growing developments for CSF management products. On the other hand, the risk associated with CSF shunts hinders the market growth.
The Canada Communicable Disease Report (CCDR), Centers for Disease Control and Prevention (CDC), European Union, Italian Trade Agency (ITA) are a few key primary and secondary sources referred to while preparing the report on the cerebrospinal fluid management market.